Diego Albrecht

Statistics

Publications

Citations

872

H-Index

Active since

2007

Affiliations

Novartis (Switzerland)(Current)

Novartis (India)

Profil Institute for Metabolic Research

Novartis (United States)

Medizinische Hochschule Hannover

Diego Albrecht is an author at Novartis (Switzerland) specializing in pharmacology, cardiovascular pharmacotherapy, and angiotensin receptor-neprilysin inhibitors.

Publications per year

2007–2018

Publications

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

Vivian Fonseca, Anja Schweizer, Diego Albrecht et al. · Diabetologia · 2007 · 370 citations · Full text

Medicine, Endocrinology, Pharmacology +13

The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study

Roland E. Schmieder, Frank Wagner, Michael Mayr et al. · European Heart Journal · 2017 · 158 citations · Full text

Medicine, Cardiology, Pharmacology +17

Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension

Jens Jordan, Rudi Stinkens, Thomas Jax et al. · Clinical Pharmacology & Therapeutics · 2016 · 124 citations

Medicine, Endocrinology, Pharmacology +16

Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (<scp>LCZ</scp>696) in Patients with Heart Failure and Reduced Ejection Fraction

Zhanna Kobalava, Yu. V. Kotovskaya, Diego Albrecht et al. · Cardiovascular Therapeutics · 2016 · 80 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor

Surya Ayalasomayajula, Thomas Langenickel, Pierre J. Jordaan et al. · European Journal of Clinical Pharmacology · 2016 · 43 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

1–5 of 9